Teladoc initiated with a Buy at Guggenheim. Guggenheim analyst Glen Santangelo initiated Teladoc with a Buy rating and a price target of $59. The analyst contends that the company stands well positioned to benefit from the “early stages of penetration” by telemedicine. Santangelo acknowledges the “competitive pressures facing the industry”, but believes that the recent pullback in the stock price positions the company as a potential “beat and raise story”.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.